European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of...
Source: Roche Media News - November 2, 2020 Category: Pharmaceuticals Source Type: news
European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of...
Source: Roche Investor Update - November 2, 2020 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changing the treatment landscape for this aggressive disease”, said Levi Ga...
Source: Roche Investor Update - October 29, 2020 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changing the treatment landscape for this aggressive disease”, said Levi Ga...
Source: Roche Media News - October 29, 2020 Category: Pharmaceuticals Source Type: news
Rurality, Income Impact Stage at Diagnosis, Mortality in Liver Cancer
MONDAY, Oct. 26, 2020 -- Patients with hepatocellular carcinoma (HCC) from rural regions and lower-income households are more likely to have advanced-stage HCC at diagnosis and higher HCC mortality, according to a study published online Oct. 26 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 26, 2020 Category: Pharmaceuticals Source Type: news
Oncotarget: Characterization of porcine hepatocellular carcinoma for liver cancer
(Impact Journals LLC) Volume 11, Issue 28 of Oncotarget features " Development and comprehensive characterization of porcine hepatocellular carcinoma for translational liver cancer investigation " by Gaba et, al. which reported that reliable development of Oncopig HCC cell lines was demonstrated through hepatocyte isolation and Cre recombinase exposure across 15 Oncopigs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 10, 2020 Category: Cancer & Oncology Source Type: news
Hepatocellular Carcinoma Shows Risk Factor Shift Hepatocellular Carcinoma Shows Risk Factor Shift
The most common form of liver cancer has seen a demographic shift, with incidence highest in the Hispanic population. The good news in HCC is that rates appear to be declining among young men.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 25, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Liquid Biopsy Might Help Detect, Manage Liver Cancer in the Future Liquid Biopsy Might Help Detect, Manage Liver Cancer in the Future
Liquid biopsy could someday be useful for the early detection and clinical management of hepatocellular carcinoma (HCC), according to a new review.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - September 22, 2020 Category: Radiology Tags: Hematology-Oncology News Source Type: news
Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expected from ...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news
Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expected from ...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news
HCV-Related Liver Cancer Incidence Dropped in US Cohort HCV-Related Liver Cancer Incidence Dropped in US Cohort
The incidence of hepatocellular carcinoma declined after widespread use of direct-acting antiviral therapies to treat hepatitis C, according to findings from a large population-based study.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 16, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Steatohepatitis Biomarkers and HCC After HCV Elimination Steatohepatitis Biomarkers and HCC After HCV Elimination
This study used steatohepatitis-related biomarkers to evaluate the development of hepatocellular carcinoma by patients with chronic hepatitis C who achieved SVR by DAA treatment.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 9, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Chemotherapy drug more effective when combined with microbubbles
(American Institute of Physics) Hepatocellular carcinoma is usually treated by blocking the flow of blood to the tumor to induce cancer cell death, but the common treatment, transarterial chemoembolization, is invasive and too imprecise to be a local drug delivery method. Aiming to increase the precision, researchers at Tulane University created a treatment that involves vaporizing tiny droplets of perfluorocarbon, a common organic material composed of carbon and fluorine. The method of gas embolization is published in APL Bioengineering. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 8, 2020 Category: International Medicine & Public Health Source Type: news
Sex Disparities in Presentation and Prognosis of HCC Sex Disparities in Presentation and Prognosis of HCC
A new study examines the sex disparities that exist in hepatocellular carcinoma presentation and prognosis. In what ways might these differences impact outcomes?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 2, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Yilmaz Mahshid takes office as CEO of Medivir on 14 September
STOCKHOLM, Aug. 18, 2020 -- (Healthcare Sales & Marketing Network) -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that Dr. Yilmaz Mahshid will assume his position as CEO on September 14, 2020. Uli Hacksell, who has been CEO since October 2018, wil... Biopharmaceuticals, Oncology, Personnel Medivir, hepatocellular carcinoma, liver cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 18, 2020 Category: Pharmaceuticals Source Type: news
